56 studies found for:    Open Studies | "Niacin"
Show Display Options
Rank Status Study
21 Recruiting Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: Quercetin
22 Recruiting Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure
Conditions: Congestive Heart Failure;   Ischemic Cardiomyopathy
Intervention: Drug: Micronutrients
23 Unknown  Study to Evaluate the Efficacy and Tolerability of Apevinat BC Compared to Vitamin Complex
Conditions: Lack of Appetite;   Anorexia
Interventions: Drug: Apevinat BC;   Drug: Vitamin Complex
24 Unknown  A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)
Condition: Schizophrenia
Intervention:
25 Recruiting A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event.
Condition: Cardiovascular Diseases
Interventions: Drug: AMR101;   Drug: Placebo
26 Recruiting Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris
Condition: Acne Vulgaris
Interventions: Drug: AGN-190168 Formulation 1;   Drug: AGN-190168 Formulation 2;   Drug: tazarotene gel 0.1%;   Drug: tazarotene cream 0.1%
27 Recruiting Effects of Micronutrient (Chromium) Supplementation on Diabetes
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: chromium niacinate;   Drug: placebo
28 Not yet recruiting Iron and Prebiotics Fortification in Kenyan Infants
Conditions: Anemia;   Iron Deficiency;   Diarrhea;   Malaria;   Respiratory Tract Infections (RTI)
Intervention: Dietary Supplement: Fortified maize porridge
29 Unknown  Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery
Condition: Liver Cancer
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
30 Recruiting Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Adult Primary Undifferentiated Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Childhood Hepatocellular Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Childhood Liver Cancer;   Stage C Adult Primary Liver Cancer (BCLC);   Stage D Adult Primary Liver Cancer (BCLC);   Stage III Childhood Liver Cancer;   Stage IV Childhood Liver Cancer
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
31 Recruiting Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: sorafenib tosylate;   Other: placebo;   Other: laboratory biomarker analysis
32 Recruiting Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: Drug: sorafenib tosylate;   Procedure: bone marrow transplantation;   Other: pharmacological study;   Other: laboratory biomarker analysis
33 Recruiting Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Salivary Gland Cancer;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   Tongue Cancer;   Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Drug: sorafenib tosylate;   Drug: cisplatin;   Drug: docetaxel;   Other: Correlative Studies
34 Recruiting Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer;   Liver Cancer
Interventions: Drug: hypoxia-activated prodrug TH-302;   Drug: sorafenib tosylate;   Genetic: protein analysis;   Other: laboratory biomarker analysis
35 Recruiting Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma
Conditions: Adult Anaplastic Astrocytoma;   Recurrent Adult Brain Tumoradult Anaplastic Meningioma;   Adult Glioblastoma;   Meningeal Melanocytoma
Interventions: Drug: sorafenib tosylate;   Drug: valproic acid;   Drug: sildenafil citrate
36 Not yet recruiting Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: navitoclax;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
37 Recruiting Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
38 Unknown  Sorafenib Tosylate With or Without Gemcitabine Hydrochloride and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
Condition: Liver Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: oxaliplatin;   Drug: sorafenib tosylate
39 Recruiting Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Conditions: Stage IIB Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: sorafenib tosylate;   Drug: epirubicin hydrochloride;   Drug: ifosfamide;   Radiation: external beam radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
40 Recruiting Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases
Condition: Tumors Metastatic to Brain
Interventions: Drug: sorafenib tosylate;   Radiation: stereotactic radiosurgery;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-56) Show next page of results
Indicates status has not been verified in more than two years